Accessibility Menu
Apg|sga logo

Apg|sga(XSWX) APGN

Market CapCHF 596.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)+221%
5 Year-9%
1 Year-10%
1 Month-0%
CHF 197.50
-0.75%
-1.50Today
Apg|sga last closing stock price
MetricPriceDate
Last closeCHF 199.002026-08-31
Apg|sga stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.49%CHF 202.002026-08-24
1 month-0.25%CHF 199.502026-07-31
3 month+10.56%CHF 180.002026-06-02
Year to date-5.24%CHF 210.002025-12-30
1 year-9.55%CHF 220.002025-08-29
3 year+9.94%CHF 181.002023-09-01
5 year-8.51%CHF 217.502021-09-01
Since inception+221.18%CHF 61.961999-08-16

Apg|sga Financials at a Glance

Market Cap

CHF 596.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.66M

EPS (TTM)

CHF 10.04

P/E Ratio

19.83

Dividend

CHF 12.00

Beta (Volatility)

0.01 (Low)

Price

CHF 197.50

Volume

5,704

Open

CHF 199.00

Previous Close

CHF 199.00

Daily Range

CHF 197.00 - CHF 199.00

52-Week Range

CHF 176.00 - CHF 223.00

Estimated Earnings Date

Nov 15, 2022

APGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Apg|sga

Apexigen, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for oncological diseases. Established in 2010 and based in San Carlos, California, the company is advancing several promising candidates in its developmental pipeline.

Products and Services
  • APX005M: A humanized agonist antibody in Phase II trials for various solid tumors
  • APX601: A humanized antagonist antibody undergoing Phase I/II trials for multiple tumor indications
  • APX801: An NK cell engager designed to stimulate natural killer cells against cancer
Growth Outlook
  • APX005M shows potential in treating melanoma and other solid tumors
  • Ongoing clinical trials may lead to significant advancements in cancer treatment
  • Strategic partnerships could enhance research capabilities and market reach
Financial Highlights
  • Q2 2023 net income of -$6.05 million, consistent with prior quarters
  • Cash and cash equivalents of $9.37 million as of June 30, 2023
  • Operating expenses of $6.16 million in Q2 2023, reflecting ongoing R&D investments
Apexigen, Inc. is positioned in the biotechnology sector, focusing on innovative therapies for cancer treatment. The company's lead product, APX005M, is currently in Phase II clinical trials, targeting various solid tumors, which could represent a significant market opportunity. The ongoing development of APX601 and APX801 further diversifies the pipeline, potentially addressing multiple cancer indications. The growth outlook remains promising, with the potential for strategic partnerships to enhance research capabilities and expand market reach. Financially, the company has maintained a consistent investment in research and development, as evidenced by the operating expenses reported in recent quarters. The cash position, while under pressure, supports ongoing clinical trials and operational needs. Overall, Apexigen, Inc. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in the area of oncology. The company's commitment to advancing innovative therapies could lead to significant breakthroughs in cancer treatment.
AI Generated • Aug 11, 2026

Industry

Media

Sector

Communication Services

Employees

516

CEO

Markus Ehrle

Website

www.apgsga.ch

Headquarters

San Carlos, CA 94070, US

APGN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

48.27%

Return on Capital

-504.18%

Return on Assets

-137.62%

Earnings Yield

5.04%

Dividend Yield

6.03%

Payout Ratio

0.00%

Stock Overview

Market Cap

CHF 596.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.00M

Volume

5.70K

Avg. Volume

2.86K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$27.82M

EBITDA

-$34.72M

Operating Cash Flow

$374.98M

Capital Expenditure

-$14.00K

Free Cash Flow

$374.97M

Cash & ST Invst.

$9.37M

Total Debt

$0.00

Apg|sga Performance Analysis

Apg|sga annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 310,600,00016.7%
20232023-12-31USD 325,632,0004.8%
20242024-12-31USD 326,945,0000.4%
20252025-12-31USD 327,032,0000.0%
Apg|sga sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30N/A
Q42022-12-31N/A
Q12023-03-31N/A
Q22023-06-30N/A
Apg|sga annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 7.8184.6%
20232023-12-31USD 8.9514.7%
20242024-12-31USD 10.1012.9%
20252025-12-31USD 9.03-10.6%
Apg|sga sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-3099.8%
Q42022-12-31-82502.5%
Q12023-03-3199.9%
Q22023-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

CHF 596.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CHF 54.23M

N/A

Employees

11

N/A

Net Income

-$6.05M

+99.6%

EBITDA

-$6.16M

+99.7%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$9.37M

-87.8%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.38%

N/A

Return on Invested Capital

-5.12%

N/A

Free Cash Flow

-$3.00M

+99.3%

Operating Cash Flow

-$3.00M

+99.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KRROKorro Bio, Inc.
$12.49-3.25%
AMTIApplied Molecular Transport Inc.
$0.26-3.13%
TSBXTurnstone Biologics Corp.
$0.36+0.00%
IMVIFIMV Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About APGN

What is the current price of Apg|sga?

Apg|sga is trading at CHF 197.50 per share.

What is the 52-week range for Apg|sga?

Over the past 52 weeks, Apg|sga has traded between CHF 176.00 and CHF 223.00.

How much debt does Apg|sga have?

As of the most recent reporting period, Apg|sga reported total debt of $0.00.

How much cash does Apg|sga have on hand?

Apg|sga reported $53.02M in cash and cash equivalents in its most recent financial results.

What is Apg|sga’s dividend yield?

Apg|sga currently has a dividend yield of 6.03%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services